Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3797 - The prognostic value of early tumor response in metastatic nasopharyngeal carcinoma patients treated with first-line chemotherapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Wei-Xiong Xia

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

W. Xia1, L. guoying1, X. Lv2, S. Lv2, X. Huang1, W. Qiu2, H. Liang2, W. Li1, K. Liu2, Y. Yu2, Y. Xiang2, X. Guo2

Author affiliations

  • 1 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou/CN
More

Resources

Abstract 3797

Background

The prognostic value of the early tumor response to first-line chemotherapy remains unknown in metastatic nasopharyngeal carcinoma (mNPC). The aim of this study was to explore the association between early tumor response (response at 6 weeks) and survival outcomes and to assess the relationship between best (response at 18 weeks) and early tumor response.

Methods

A total of 433 mNPC patients with measurable lesions, who received first line chemotherapy between 2005 and 2016 were enrolled in this study. Response was assessed at completion of 6 weeks and 18 weeks of chemotherapy using RECIST 1.1. To estimate in an unbiased way, the landmark method was used in this study. Log-rank test and Cox regression were used to analyze survival data. The correlation between early tumor response and best tumor response was measured by Kappa agreement, Pearson correlation and receiver operating curves.

Results

The median follow-up time was 54.3 months (IQR: 38.6-79 months). Two hundred and sixty-five patients achieved tumor response at 6 weeks. From the 6-week landmark, patients with tumor response were significantly associated with better OS (hazard ratio, HR = 0.566, P < 0.001, median OS: 30.3 versus 21.7 months) and PFS (HR = 0.426, P < 0.001, median PFS: 9.2 versus 7.3 months) than the patients without. After adjusting for potential confounders, the early tumor response was an independent prognostic factor associated with OS (HR = 0.539, 95% CI, 0.428 to 0.679, P < 0.001) and PFS (HR = 0.467, 95% CI, 0.378 to 0.576, P < 0.001), respectively. There was a good correlation between the early and best tumor response (Kappa: 0.82; Pearson: 0.83). The sensitivity, specificity, positive and negative predictive values of early tumor response in predicting best response were 100%, 79%, 88% and 100%.

Conclusions

Early tumor response is an independent prognostic factor in determining survival. The early and best tumor response correlated very well. The data could provide a basis for trial design that addresses alteration of first line chemotherapy intensity. Validation studies are awaited.

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center.

Funding

National Natural Science Foundation of China.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.